Meeting
2023 ASCO Annual Meeting
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).
Authors
Monzr M. Al Malki
City of Hope, Duarte, CA
Monzr M. Al Malki , Sumithira Vasu , Dipenkumar Modi , Suzanne D Afonso-Smith , Sojung Kim , Emily Lu , Guido Marcucci , Mathias Oelke , Robert D. Knight , Juan Carlos Varela
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04284228
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7043)
DOI
10.1200/JCO.2023.41.16_suppl.7043
Abstract #
7043
Poster Bd #
173
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Donor-derived T cells specific for tumor antigen and multiple pathogens for prevention of relapse and infection after haemopoietic stem cell transplant (HSCT) for myeloid malignancies (the INTACT trial).
First Author: Wei Jiang
Poster
2022 ASCO Annual Meeting
Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
First Author: Jing Pan
Poster
2022 ASCO Annual Meeting
A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
First Author: Brian Gastman
Poster
2024 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors.
First Author: Panpan Zhang